Sector News

EMA chief Rasi kicked out as tribunal annuls appointment

November 14, 2014
Life sciences
The European Medicines Agency’s executive director Guido Rasi has been forced to step down after his appointment, made three years, was annulled by a EU panel.
 
The European Union Civil Service Tribunal has ruled on an appeal by an individual against the selection procedure in 2011 for the appointment of executive director of the EMA. The unnamed person brought the case in January 2012 following the decision by the European Commission not to include him on the shortlist of candidates.
 
The court has, “on purely formal grounds”, annulled the Commission’s decision of adopting a shortlist and as a consequence, the choice of Dr Rasi (pictured) has also been annulled.
 
Sir Kent Woods, chair of the EMA management board, noted “with regret” the tribunal’s judgement, saying “it is important to remember that the ruling is about a procedural formality. It is not a reflection on Guido Rasi’s competence or ability to run the agency, something which he has done successfully since November 2011.”
 
The European Commission and EMA are both taking legal advice. “Pending further decisions”, Andreas Pott, the agency’s deputy executive director, will take over.
 
By Kevin Grogan
 
Source: Pharma Times
 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach